Matthew N. Klein

Matthew N. Klein

Auto-generated profile, based on publicly available information

Matthew N. Klein

College of Medicine, Drexel University, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
VXVincent Eric Xu
Vincent Eric Xu
OAOluwafolajimi Adesanya
Oluwafolajimi Adesanya
SASarah Azari
Sarah Azari
SISamita Islam
Samita Islam
MKMatthew Klein
Matthew Klein
MWMichael Whalen
Michael Whalen

19 November 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
MKMatthew N. Klein
Matthew N. Klein
ELEmily J. Larkin
Emily J. Larkin
JMJuliana N. Marshall
Juliana N. Marshall
XFXiaoxuan Fan
Xiaoxuan Fan
PPPhilippe Parry
Philippe Parry
MFMagali J. Fontaine
Magali J. Fontaine

28 March 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
JMJuliana N. Marshall
Juliana N. Marshall
MKMatthew N. Klein
Matthew N. Klein
PKPratap Karki
Pratap Karki
KPKamoltip Promnares
Kamoltip Promnares
SSSaini Setua
Saini Setua
MFMagali J. Fontaine
Magali J. Fontaine
Glycophorin A (GPA), a red blood cell (RBC) surface glycoprotein, can maintain peripheral blood leukocyte quiescence through interaction with a sialic acid–binding Ig-like lectin (Siglec-9). Under inflammatory conditions such as sickle cell disease (SCD), the GPA of RBCs undergo structural changes that affect this interaction. Peripheral blood samples from patients with SCD before and after RBC transfusions were probed for neutrophil and monocyte activation markers and analyzed by fluorescence-activated cell sorting (FACS). RBCs were purified and tested by FACS for Siglec-9 binding and GPA expression, and incubated with cultured endothelial cells to evaluate their effect on barrier function. Activated leukocytes from healthy subjects (HS) were coincubated with healthy RBCs (RBCH), GPA-altered RBCs, or GPA-overexpressing (OE) cells and analyzed using FACS. Monocyte CD63 and neutrophil CD66b from patients with SCD at baseline were increased 47% and 27%, respectively, as compared with HS (P = .0017, P = .0162). After transfusion, these markers were suppressed by 22% and 17% (P = .0084, P = .0633). GPA expression in RBCSCD was 38% higher (P = .0291) with decreased Siglec-9 binding compared with RBCH (0.0266). Monocyte CD63 and neutrophil CD66b were suppressed after incubation with RBCH and GPA-OE cells, but not with GPA-altered RBCs. Endothelial barrier dysfunction after lipopolysaccharide challenge was restored fully with exposure to RBCH, but not with RBCSCD, from patients in pain crisis, or with RBCH with altered GPA. Pretransfusion RBCSCD do not effectively maintain the quiescence of leukocytes and endothelium, but quiescence is restored through RBC transfusion, likely by reestablished GPA-Siglec-9 interactions.

10 February 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MKMatthew N. Klein
Matthew N. Klein
OAOluwafolajimi Adesanya
Oluwafolajimi Adesanya
VXVincent Eric Xu
Vincent Eric Xu
OGOlivia Gordon
Olivia Gordon
RARyan M. Antar
Ryan M. Antar
MWMichael Whalen
Michael Whalen

8 February 2024 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
SPStephanie Papillon
Stephanie Papillon
SMSahal Master
Sahal Master
MKMatthew Klein
Matthew Klein
ATAllison Toth
Allison Toth
NANorrell Atkinson
Norrell Atkinson
HGHarsh Grewal
Harsh Grewal